Cellmid Limited (ASX: CDY) has reported that it received notice of allowance from the USPTO for the improved midkine antibody patent. Further, the European Patent Office has issued a ‘Decision to Grant’ for the improved midkine antibody patent.
- The developments reflect major milestones in the midkine therapeutic program.
- It adds significant commercial value and intellectual property to the portfolio.
- It stems the intellectual property position of the company on the use of midkine therapeutic antibodies for treatments.
- CDY’s midkine patent portfolio includes 67 patents and application in 12 patent families.
By 1:04 PM AEDT, CDY was trading at $0.225, up by 7.14 per cent from the previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.